AAP
AXSM icon

Arax Advisory Partners’s Axsome Therapeutics AXSM Stock Holding History

Arax Advisory Partners’s Portfolio AXSM Stock Details AXSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$20.7K Sell
107
-87
-45% -$15K ﹤0.01% 2095
2025
Q4 		$35.4K Sell
194
-2,513
-93% -$351K ﹤0.01% 1798
2025
Q3 		$329K Buy
2,707
+2,640
+3,940% +$297K ﹤0.01% 1067
2025
Q2 		$7K Hold
67
– – ﹤0.01% 2117
2025
Q1 		$7.81K Buy
67
+49
+272% +$5.58K ﹤0.01% 1633
2024
Q4 		$1.52K Buy
18
+7
+64% +$644 ﹤0.01% 2075
2024
Q3 		$989 Buy
+11
New +$960 ﹤0.01% 2265

Other funds holding AXSM

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Arax Advisory Partners's AXSM Position: Q1 2026 in Review

Arax Advisory Partners reduced its Axsome Therapeutics (AXSM) stake by 45% in Q1 2026, selling an estimated $15K and leaving 107 shares worth $20.7K. The position accounts for ﹤0.01% of the portfolio, ranked #2095.

Arax Advisory Partners first reported a position in AXSM in Q3 2024 and has held it in 7 quarters since. The position peaked at $329K in Q3 2025. 409 funds tracked by Wall St. Rank hold AXSM as of Q1 2026.

  • Arax Advisory Partners held 107 shares of Axsome Therapeutics worth $20.7K as of Q1 2026.
  • Arax Advisory Partners sold 87 Axsome Therapeutics shares in Q1 2026, an estimated $15K.
  • Axsome Therapeutics made up ﹤0.01% of Arax Advisory Partners's portfolio in Q1 2026, its #2095 holding.
  • Arax Advisory Partners first reported a position in Axsome Therapeutics in Q3 2024 and has held it in 7 quarters since.
  • Arax Advisory Partners's Axsome Therapeutics position peaked at $329K in Q3 2025.
  • 409 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q1 2026.

Based on Arax Advisory Partners's 13F filing for Q1 2026, filed 13 May 2026.